Physicians' Academy for Cardiovascular Education
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.
The designation is granted for the ongoing EMPEROR program, which evaluates treatment with empagliflozin for the reduction of the risk of CV death and hospitalisation for HF in chronic HFrEF and HFpEF.
ERA-EDTA 2019 Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.
EuroPrevent 2019 Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.
EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how we can modify CVD risk factors in these patients.
EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.
In the follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.
Prof. Adriaan Voors addresses 3 major questions on the future of SGLT2i in HF: on routinely use in T2DM and HF, use in HF without T2DM, and ongoing trials.
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.
ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.
What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.
ERA-EDTA 2019 In an analysis of the CARMELINA trial, linagliptin therapy did not result in improvement of eGFR and CV events in diabetes patients with or without nephrotic-range proteinuria.
